BRPI0813269A2 - Inibidores de hiv transcriptase reversa - Google Patents

Inibidores de hiv transcriptase reversa

Info

Publication number
BRPI0813269A2
BRPI0813269A2 BRPI0813269-0A2A BRPI0813269A BRPI0813269A2 BR PI0813269 A2 BRPI0813269 A2 BR PI0813269A2 BR PI0813269 A BRPI0813269 A BR PI0813269A BR PI0813269 A2 BRPI0813269 A2 BR PI0813269A2
Authority
BR
Brazil
Prior art keywords
transcriptase inhibitors
reverse hiv
hiv transcriptase
reverse
inhibitors
Prior art date
Application number
BRPI0813269-0A2A
Other languages
English (en)
Inventor
Hongyan Guo
Choung U Kim
Young Lee Iii
Michael L Mitchell
Gerry Rhodes
Jong Chan Son
Lianhong Xu
Original Assignee
Korean Res Inst Of Chemical Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korean Res Inst Of Chemical Technology filed Critical Korean Res Inst Of Chemical Technology
Publication of BRPI0813269A2 publication Critical patent/BRPI0813269A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0813269-0A2A 2007-06-29 2008-06-26 Inibidores de hiv transcriptase reversa BRPI0813269A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93775607P 2007-06-29 2007-06-29
US95967607P 2007-07-16 2007-07-16
PCT/US2008/007925 WO2009005674A2 (en) 2007-06-29 2008-06-26 Novel hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0813269A2 true BRPI0813269A2 (pt) 2014-12-30

Family

ID=39790161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813269-0A2A BRPI0813269A2 (pt) 2007-06-29 2008-06-26 Inibidores de hiv transcriptase reversa

Country Status (15)

Country Link
US (2) US8334295B2 (pt)
EP (1) EP2167476B1 (pt)
JP (1) JP2010532350A (pt)
KR (1) KR101551238B1 (pt)
CN (1) CN101784532B (pt)
AR (1) AR067181A1 (pt)
AU (1) AU2008271114A1 (pt)
BR (1) BRPI0813269A2 (pt)
CA (1) CA2692460A1 (pt)
EA (1) EA200971115A1 (pt)
ES (1) ES2533863T3 (pt)
MX (1) MX2009013804A (pt)
TW (1) TW200918507A (pt)
WO (1) WO2009005674A2 (pt)
ZA (1) ZA201000023B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544710A (ja) * 2006-07-24 2009-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ逆転写酵素インヒビター
KR20100041798A (ko) * 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
WO2009085797A1 (en) * 2007-12-21 2009-07-09 Gilead Sciences, Inc. Processes for preparing hiv reverse transcriptase inhibitors
US8445669B2 (en) * 2008-04-10 2013-05-21 Hamari Chemicals, Ltd. Production process of ethynylthymidine compounds from 5-methyluridine as a starting material
US8604193B2 (en) 2009-01-26 2013-12-10 Korea Research Institute Of Chemical Technology Processes for preparing HIV reverse transcriptase inhibitors
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
PE20121524A1 (es) 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
PL2528923T3 (pl) 2010-01-28 2015-01-30 Mapi Pharma Ltd Sposób wytwarzania darunawiru i pochodnych darunawiru
MD20140044A2 (ro) 2011-11-11 2014-08-31 Pfizer Inc. 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
EP2852583A1 (en) 2012-05-23 2015-04-01 Bristol-Myers Squibb Company Sulfilimine and sulphoxide methods for producing festinavir
CA2897444A1 (en) * 2013-01-08 2014-07-17 Genzyme Corporation Use of inos inhibitors to increase viral yield in culture
US20160060252A1 (en) 2013-04-16 2016-03-03 Bristol-Myers Squibb Company 5-methyluridine method for producing festinavir
WO2014201122A1 (en) 2013-06-13 2014-12-18 Bristol-Myers Squibb Company Tert-butyl-sulphoxide method for producing festinavir
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
EP3383863A1 (en) 2015-12-04 2018-10-10 ViiV Healthcare UK Limited Isoindoline derivatives
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
AR109950A1 (es) * 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN106831608A (zh) * 2017-02-16 2017-06-13 江苏艾迪药业有限公司 一种化合物的新晶型及其制备方法与应用
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
JPWO2023195529A1 (pt) 2022-04-08 2023-10-12
CN115536596A (zh) * 2022-11-08 2022-12-30 巨鑫生物制药股份有限公司 一种acc007中间体的制备方法
CN116640068A (zh) * 2023-05-26 2023-08-25 康化（上海）新药研发有限公司 一种（3-环丙基-2-炔-1-基）甘氨酸苄酯的合成方法
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126148A1 (en) * 1971-05-26 1972-12-07 Farbenfabriken Bayer Ag, 5090 Leverkusen Prepn of uracil derivs - useful as plant - protection agents and their inters
DE2142317A1 (de) * 1971-08-24 1973-03-01 Bayer Ag Hypnotisches mittel
US4656209A (en) 1982-05-26 1987-04-07 Ciba-Geigy Corporation Chlorinated thermoplastics stabilized with aminouracils
JPS59201057A (ja) 1983-04-18 1984-11-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US4649142A (en) * 1984-06-25 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
ES2013664A6 (es) 1988-03-31 1990-05-16 Mitsubishi Chem Ind Un procedimiento para preparar derivados de nucleosidos de aciclopiramidina sustituidos en la posicion 6.
WO1989010701A1 (fr) 1988-05-05 1989-11-16 Basf Aktiengesellschaft Produits a base de derives d'uracil pour stimuler la croissance et reduire la graisse chez les animaux
US5219869A (en) 1989-05-17 1993-06-15 Nihon Bayer Agrochem K.K. Nitro-substituted heterocyclic compounds
KR0155168B1 (ko) 1989-09-29 1998-11-16 미우라 아끼라 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
JPH0751567B2 (ja) * 1989-09-29 1995-06-05 三菱化学株式会社 ６―置換アシクロピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤
US5162326A (en) 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
JP2860689B2 (ja) 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
CA2039039C (en) 1990-03-29 2001-05-15 Tadashi Miyasaka Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient
EP0539588A1 (en) 1990-07-05 1993-05-05 Nippon Soda Co., Ltd. Amine derivative
JPH04166930A (ja) 1990-10-31 1992-06-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPH04166931A (ja) 1990-10-31 1992-06-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JP2739260B2 (ja) 1991-04-10 1998-04-15 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
AU1994492A (en) 1991-07-22 1993-02-23 Baker Cummins Pharmaceuticals, Inc. Acyclic 6-phenylselenenyl pyrimidine nucleosides
DE4204031A1 (de) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
DE4204032A1 (de) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
JPH05289238A (ja) 1992-04-08 1993-11-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPH06135943A (ja) 1992-09-14 1994-05-17 Japan Energy Corp 新規なウラシル誘導体及びそれを有効成分とするアレルギー疾患治療薬
WO1994027975A1 (de) * 1993-05-21 1994-12-08 Pentapharm Ag 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
KR0151811B1 (ko) * 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법
EP0748316B1 (en) 1994-02-28 2002-05-08 Sunkyong Industries Co., Ltd. Pyrimidine acyclonucleoside derivatives
JP3264579B2 (ja) 1994-03-18 2002-03-11 扶桑薬品工業株式会社 クラミジア・トラコマチス血清型の鑑別法
JPH083143A (ja) 1994-06-21 1996-01-09 Mitsubishi Chem Corp ６−アラルキル置換ピリミジン誘導体の製造方法
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH0920792A (ja) 1995-07-11 1997-01-21 Soyaku Gijutsu Kenkyusho:Kk ヌクレオチドダイマー
DE69628750T2 (de) * 1996-02-22 2004-04-29 Samjin Pharm, Co., Ltd. Neue antivirale, homocarbozklische nukleosidderivate von substituierten pyrimidindionen, verfahren zu ihrer herstellung und zusammensetzungen, die diese als aktiven bestandteil enthalten
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
JPH10130244A (ja) 1996-09-06 1998-05-19 Mitsubishi Chem Corp アシクロヌクレオシドの製造方法
JPH10130245A (ja) 1996-09-06 1998-05-19 Mitsubishi Chem Corp アシクロヌクレオシドの製造方法
MY114466A (en) 1996-09-25 2002-10-31 Crompton Vinyl Additives Gmbh Rigid pvc stabilised with n, n-dimethyl-6-aminouracils
JPH10168068A (ja) 1996-12-05 1998-06-23 Mitsubishi Chem Corp アシクロヌクレオシドの製造方法
ZA98566B (en) 1997-01-31 1998-07-30 Mitsubishi Chem Corp Antiviral agents
JPH11102047A (ja) 1997-09-26 1999-04-13 Fuji Photo Film Co Ltd 熱現像画像形成材料
US5998411A (en) * 1998-03-17 1999-12-07 Hughes Institute Heterocyclic nonnucleoside inhibitors of reverse transcriptase
FR2779721A1 (fr) 1998-06-15 1999-12-17 Expansia Sa Substitution d'une 1,5-dialkyl uracile en position 6
FR2779722A1 (fr) 1998-06-15 1999-12-17 Expansia Sa Hydrogenation de 6-alpha-alkylcarboxy methylaryl-1,5-dialkyl uracile
DK0967209T3 (da) 1998-06-26 2003-03-24 Crompton Vinyl Additives Gmbh Hidtil ukendte NH2-modificerede 6-aminouraciler som stabilisatorer af halogenholdige polymerer
US6177437B1 (en) 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
WO2000051990A1 (en) * 1999-03-04 2000-09-08 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
KR20000065885A (ko) * 1999-04-10 2000-11-15 최승주 항바이러스성 피리미딘다이온 유도체 및 그 제조방법
AU7450300A (en) 1999-09-29 2001-04-30 Sankyo Company Limited Sulfonamide derivatives
JP2001114767A (ja) 1999-10-15 2001-04-24 Sumika Fine Chemicals Co Ltd ピリミジン化合物の製造方法、およびその中間体の製造方法
AU2001263864A1 (en) 2000-04-17 2001-10-30 Basf Aktiengesellschaft Herbicidal 3-heterocyclic substituted benzisothiazole and benzisoxazole compounds
HU229494B1 (en) 2000-05-04 2014-01-28 Basf Ag Uracil substituted phenyl sulfamoyl carboxamides
US6911450B1 (en) 2001-01-29 2005-06-28 Universite De Geneve Pyrimidine acyclonucleoside derivatives, preparation method and use thereof
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
WO2003029226A1 (en) 2001-09-26 2003-04-10 Basf Aktiengesellschaft Heterocyclyl substituted phenoxyalkyl-, phenylthioalkyl-, phenylaminoalkyl- and phenylalkyl-sulfamoylcarboxamides
AU2003205536A1 (en) 2002-01-11 2003-07-24 Statens Serum Institut Anti-retroviral 5,6-disubstituted acyclopyrimidine nucleoside derivatives
CN1625579A (zh) 2002-01-31 2005-06-08 西巴特殊化学品控股有限公司 与加氯水永久接触的聚烯烃的稳定化
AU2003231765B9 (en) 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
MXPA05001783A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
US20050026902A1 (en) 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
US7947817B2 (en) 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
EP1685127A1 (en) 2003-11-21 2006-08-02 The University of Connecticut Heterocyclyl-substituted oxetanes for the treatment of proliferative or infectious diseases
MXPA03011298A (es) 2003-12-08 2005-06-10 Ct Investig Y Estudios Del Ipn Compuestos 5'-nor-1-homo-n-carbonucleosidos y proceso de obtencion de los mismos.
JP2005212143A (ja) 2004-01-27 2005-08-11 Fuji Photo Film Co Ltd 記録材料
WO2006070292A2 (en) 2004-10-12 2006-07-06 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060223834A1 (en) 2005-04-04 2006-10-05 Vasu Nair Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae
KR101237312B1 (ko) * 2006-02-10 2013-03-04 삼진제약주식회사 피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
WO2007106450A2 (en) 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
FI20065162A0 (fi) 2006-03-13 2006-03-13 Wallac Oy Terminoivia DNA polymeraasisubstraatteja
JP2009544710A (ja) 2006-07-24 2009-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ逆転写酵素インヒビター
CN101016265A (zh) 2007-03-15 2007-08-15 首都医科大学 一种新型hiv－1逆转录酶抑制剂的制备及其用途
WO2009085797A1 (en) * 2007-12-21 2009-07-09 Gilead Sciences, Inc. Processes for preparing hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
KR101551238B1 (ko) 2015-09-09
ES2533863T3 (es) 2015-04-15
JP2010532350A (ja) 2010-10-07
CN101784532B (zh) 2014-10-22
TW200918507A (en) 2009-05-01
CN101784532A (zh) 2010-07-21
AR067181A1 (es) 2009-09-30
EP2167476A2 (en) 2010-03-31
KR20100041799A (ko) 2010-04-22
ZA201000023B (en) 2011-04-28
EA200971115A1 (ru) 2010-04-30
US8334295B2 (en) 2012-12-18
WO2009005674A2 (en) 2009-01-08
US20110076276A1 (en) 2011-03-31
EP2167476B1 (en) 2015-02-25
US20130078256A1 (en) 2013-03-28
WO2009005674A3 (en) 2009-09-24
CA2692460A1 (en) 2009-01-08
MX2009013804A (es) 2010-02-03
AU2008271114A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
BRPI0813269A2 (pt) Inibidores de hiv transcriptase reversa
AP2514A (en) HIV reverse transcriptase inhibitors
ATE503744T1 (de) Nicht-nukleosidische reverse-transkriptase-hemmer
CY2017016I2 (el) Αναστολεις πρωτεασωματος
EP2076492A4 (en) NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
NO20161397A1 (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer
EP2220091A4 (en) REVERSE transcriptase inhibitors
IL188615A0 (en) Hiv reverse transcriptase inhibitors
IL199103A0 (en) Non-nucleoside reverse transcriptase inhibitors
EP2123302A4 (en) INHIBITOR OF CHRONIC EXHAUSTION
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
IL205386A0 (en) Non - nucleoside reverse transcriptase inhibitors
DE602008001705D1 (de) Bohrwerkzeug
EP2217069A4 (en) INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
EP2127790A4 (en) Drilling apparatus
BRPI0811145A2 (pt) Composto tetraidroisoquinolina 1-substituído
EP2099789A4 (en) INHIBITORS OF HIV REPLICATION
EP2116533A4 (en) Glucokinase AKTIVATOR
BRPI0811645A2 (pt) Inibidores de transcriptase reversa de não-nucleosídeo
BRPI0810496A2 (pt) inibidores de transcriptase reversa de não-nucleosídeo
BRPI0714509A2 (pt) Inibidores de transcriptase reversa de não-nucleosídeo.
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
ZA200800185B (en) Hiv reverse transcriptase inhibitors
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
DK2221296T3 (da) Kondenserede indanforbindelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.